Description de l'entreprise
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to helps clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring in post-surgical wards, reduce rapid response activations and costs.
Conseil d'administration & Conseil de surveillance
| PDG |
| Joe E. Kiani |
| Conseil d'administration |
| Micah Young, Bilal Muhsin, Tao Levy, Tom McClenahan |
| Conseil de surveillance |
| Joe E. Kiani, Adam Mikkelson, Craig B. Reynolds, Dr. Julie A. Shimer, H. Michael Cohen |
Données de l'entreprise
| Nom: |
Masimo Corp. |
| Adresse: |
52 Discovery,Irvine, California 92618, USA |
| Téléphone: |
+1-949-297-7000 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
www.masimo.com |
| Industrie: |
Healthcare |
| Secteur: |
Healthcare Providers |
| Sous-secteur: |
Healthcare Providers |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
60.90% |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
Eli Kammerman |
| Téléphone IR: |
+1-949-297-7077 |
| IR-Fax: |
- |
| E-mail IR: |
ekammerman@masimo.com
|
